Friday, September 30, 2022


Biotechnology News Magazine

U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Nicox SA (Euronext Paris: FR0013018124, COX) is an international ophthalmology company.

Today they announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the U.S. patent covering the use of latanoprostene bunod for the treatment of normal tension glaucoma. Latanoprostene bunod ophthalmic solution, 0.024%, is commercialized as VYZULTA®, for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension in the United States and other territories that have the same indication.

Normal tension glaucoma, also known as low tension or normal pressure glaucoma, is a form of glaucoma in which damage occurs to the optic nerve at intraocular pressure (IOP) within the normal range (less than 21 mmHg). Normal-tension glaucoma is typically treated by reducing the eye pressure using medications, laser treatments, and/or conventional surgery.

VYZULTA is commercialized by Nicox’s exclusive global licensee Bausch + Lomb in the U.S. (since 2017), Canada (2019), Argentina (2020), Mexico (2020), and Hong Kong (2020), and is now approved in 5 other territories (Brazil, Colombia, South Korea, Taiwan, and Ukraine).

Under the terms of the exclusive global license agreement with Bausch + Lomb, Nicox receives increasing tiered royalties of 6% to 12% on net global sales of VYZULTA plus up to $150 million in potential future milestone payments.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine